Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Koen Andries"'
Autor:
Aurélie Chauffour, Nacer Lounis, Koen Andries, Vincent Jarlier, Nicolas Veziris, Alexandra Aubry
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 11, p e0011379 (2023)
BackgroundBedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal effective dose (MED) of BDQ administered orally, (
Externí odkaz:
https://doaj.org/article/23001d8abd804ff4afba75c4cf2f112b
Autor:
Aurélie Chauffour, Nacer Lounis, Koen Andries, Vincent Jarlier, Nicolas Veziris, Alexandra Aubry
BackgroundBedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal effective dose (MED) of oral BDQ, (ii) evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2abd6a7ae3fcd4f24c76cd1243882b4
https://doi.org/10.1101/2023.05.15.540907
https://doi.org/10.1101/2023.05.15.540907
Autor:
Paul Meyvisch, Chrispin Kambili, Koen Andries, Nacer Lounis, Myriam Theeuwes, Brian Dannemann, An Vandebosch, Wim Van der Elst, Geert Molenberghs, Ariel Alonso
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0200539 (2018)
The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints for
Externí odkaz:
https://doaj.org/article/03094ade65714b5fa70d067772889bc2
Autor:
Vadim Makarov, Benoit Lechartier, Ming Zhang, João Neres, Astrid M van derSar, Susanne A Raadsen, Ruben C Hartkoorn, Olga B Ryabova, Anthony Vocat, Laurent A Decosterd, Nicolas Widmer, Thierry Buclin, Wilbert Bitter, Koen Andries, Florence Pojer, Paul J Dyson, Stewart T Cole
Publikováno v:
EMBO Molecular Medicine, Vol 6, Iss 3, Pp 372-383 (2014)
Abstract The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containin
Externí odkaz:
https://doaj.org/article/7fcc7ed7ee8f414d915598d5dc239ac7
Autor:
Armando M. De Palma, Gerhard Pürstinger, Eva Wimmer, Amy K. Patick, Koen Andries, Bart Rombaut, Erik De Clercq, Johan Neyts
Publikováno v:
Emerging Infectious Diseases, Vol 14, Iss 4, Pp 545-551 (2008)
In 1988, the World Health Assembly launched the Global Polio Eradication Initiative, which aimed to use large-scale vaccination with the oral vaccine to eradicate polio worldwide by the year 2000. Although important progress has been made, polio rema
Externí odkaz:
https://doaj.org/article/18802426a8f54f95b6c17dc8ed0851d3
Autor:
Gabriela Ispas, Anil Koul, Johan Verbeeck, Jennifer Sheehan, Brigitte Sanders-Beer, Dirk Roymans, Koen Andries, Marie-Claude Rouan, Sandra De Jonghe, Jean-François Bonfanti, Marc Vanstockem, Kenneth Simmen, Rene Verloes
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126959 (2015)
BackgroundThe study assessed the antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a preclinical non-human primate challenge model with a viral shedding pattern similar to that seen in humans, following continu
Externí odkaz:
https://doaj.org/article/f305416d7c6540b8927222167c47ba8d
Autor:
Koen Andries, Cristina Villellas, Nele Coeck, Kim Thys, Tom Gevers, Luc Vranckx, Nacer Lounis, Bouke C de Jong, Anil Koul
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e102135 (2014)
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non
Externí odkaz:
https://doaj.org/article/4e20d166193842fdbc285fe8879fc250
Publikováno v:
PLoS ONE, Vol 6, Iss 3, p e17556 (2011)
RationaleThe sterilizing activity of the regimen used to treat multidrug resistant tuberculosis (MDR TB) has not been studied in a mouse model.Objective and methodsSwiss mice were intravenously inoculated with 6 log10 of Mycobacterium tuberculosis (T
Externí odkaz:
https://doaj.org/article/5b41338aa1a849aea4a30571471ea535
Autor:
Anna C Haagsma, Ioana Podasca, Anil Koul, Koen Andries, Jerome Guillemont, Holger Lill, Dirk Bald
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23575 (2011)
Infections with Mycobacterium tuberculosis are substantially increasing on a worldwide scale and new antibiotics are urgently needed to combat concomitantly emerging drug-resistant mycobacterial strains. The diarylquinoline TMC207 is a highly promisi
Externí odkaz:
https://doaj.org/article/c984effecc89411ab72dc82c07f6ee33
Autor:
Diana A. Aguilar-Ayala, Margo Cnockaert, Peter Vandamme, Emmanuel André, Anandi Martin, Jorge A. Gonzalez-y-Merchand, Juan Carlos Palomino, Koen Andries
Publikováno v:
JOURNAL OF MEDICAL MICROBIOLOGY
Journal of Medical Microbiology
Journal of Medical Microbiology
Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The objective of this study was to eval